neweastbio@126.com
PRODUCT CENTER
武漢紐斯特生物技術(shù)有限公司(Wu Han NewEast Biosciences Co., LTD)自2006年創(chuàng)辦以來,一直致力于生物醫(yī)藥領(lǐng)域高技術(shù)產(chǎn)品的研發(fā)和銷售。公司經(jīng)過多年的研發(fā)目前有三大類特色的產(chǎn)品?G蛋白信號轉(zhuǎn)導(dǎo)活性抗體/G蛋白活性檢測試劑盒,基于單抗的 CAMP/CGMP ELISA 檢測試劑盒,和腫瘤靶向治療的診斷抗體,并在美國成立了銷售子公司 “NewEast Biosciences”經(jīng)過多年來的努力與堅(jiān)持,我們的產(chǎn)品已經(jīng)協(xié)助發(fā)表了超1000篇SCI文獻(xiàn),其中包括行業(yè)頂級期刊 Nature Medicine, Nature, Cell, Cancer Cell, Cancer Discovery Nature Immunology Cell Research 等。部分高分文獻(xiàn)如下
Preclinical Assessment of AMG 596, a Bispecific T-cell Engager (BiTE) Immunotherapy Targeting the Tumor-specific Antigen EGFRvIII
2024-10-10發(fā)表時(shí)間: | 2021 |
名稱/貨號: | Anti- EGFR(vIII) Mouse Monoclonal Antibody/26176 |
影響因子: | Mol Cancer Ther IF=5.3 |
應(yīng)用范圍: | IHC |
種屬: | Human |
Immunohistochemistry with a novel mutation-specific monoclonal antibody as a screening tool for the EGFR L858R mutational status in primary lung adenocarcinoma
2024-10-10發(fā)表時(shí)間: | 2015 |
名稱/貨號: | Anti- EGFR(L858R) Mouse Monoclonal Antibody/ 26082 |
影響因子: | Tumour Biol |
應(yīng)用范圍: | IHC(作為臨床診斷的應(yīng)用工具) |
種屬: | Human(肺腺癌) |
Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism
2024-10-10發(fā)表時(shí)間: | 2015 |
名稱/貨號: | Anti- IDH1(R132H) Mouse Monoclonal Antibody /26081 |
影響因子: | J Neurochem IF=4.5 |
應(yīng)用范圍: | WB IHC |
種屬: | Human |
Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism
2024-10-10發(fā)表時(shí)間: | 2015 |
名稱/貨號: | Anti- IDH2(R172K) Mouse Monoclonal Antibody /26163 |
影響因子: | J Neurochem IF=4.5 |
應(yīng)用范圍: | WB IHC |
種屬: | Human |
The pathological features of angioimmunoblastic T-cell lymphomas with IDH2 R172 mutations
2024-10-10發(fā)表時(shí)間: | 2016 |
名稱/貨號: | Anti- IDH1(R132H) Mouse Monoclonal Antibody /26081 |
影響因子: | PLoS One IF=2.9 |
應(yīng)用范圍: | IHC(作為臨床診斷的應(yīng)用工具) |
種屬: | Human (神經(jīng)膠質(zhì)瘤) |
The pathological features of angioimmunoblastic T-cell lymphomas with IDH2 R172 mutations
2024-10-10發(fā)表時(shí)間: | 2016 |
名稱/貨號: | Anti- IDH2(R172K) Mouse Monoclonal Antibody /26163 |
影響因子: | PLoS One IF=2.9 |
應(yīng)用范圍: | IHC(作為臨床診斷的應(yīng)用工具) |
種屬: | Human (神經(jīng)膠質(zhì)瘤) |
Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy
2024-10-10發(fā)表時(shí)間: | 2019-06-01 |
名稱/貨號: | Anti -IDH2 (R140Q) Mouse Monoclonal Antibody /26165 |
影響因子: | Cell Res |
應(yīng)用范圍: | IHC(作為臨床診斷的應(yīng)用工具) |
種屬: | Human(AML) |
The pathological features of angioimmunoblastic T-cell lymphomas with IDH2 R172 mutations
2024-10-10發(fā)表時(shí)間: | 2019-07-11 |
名稱/貨號: | Anti- IDH2(R172K) Mouse Monoclonal Antibody /26163 |
影響因子: | Mod Pathol IF=7.1 |
應(yīng)用范圍: | IHC(作為臨床診斷的應(yīng)用工具) |
種屬: | Human (T細(xì)胞淋巴癌) |
Molecular epidemiology of IDH2 hotspot mutations in cancer and immunohistochemical detection of R172K, R172G, and R172M variants
2024-10-10發(fā)表時(shí)間: | 2020-12 |
名稱/貨號: | Anti- IDH2(R172W) Mouse Monoclonal Antibody/26164 |
影響因子: | Hum Pathol IF=2.7 |
應(yīng)用范圍: | IHC(作為臨床診斷的應(yīng)用工具) |
種屬: | Human |
Molecular epidemiology of IDH2 hotspot mutations in cancer and immunohistochemical detection of R172K, R172G, and R172M variants
2024-10-10發(fā)表時(shí)間: | 2020-12 |
名稱/貨號: | Anti- IDH2(R172G) Mouse Monoclonal Antibody/26231 |
影響因子: | Hum Pathol IF=2.7 |
應(yīng)用范圍: | IHC(作為臨床診斷的應(yīng)用工具) |
種屬: | Human(軟骨肉瘤,T細(xì)胞淋巴癌,鼻竇癌) |
Molecular epidemiology of IDH2 hotspot mutations in cancer and immunohistochemical detection of R172K, R172G, and R172M variants
2024-10-10發(fā)表時(shí)間: | 2020-12 |
名稱/貨號: | Anti- IDH2(R172K) Mouse Monoclonal Antibody/26163 |
影響因子: | Hum Pathol IF=2.7 |
應(yīng)用范圍: | IHC(作為臨床診斷的應(yīng)用工具) |
種屬: | Human(神經(jīng)膠質(zhì)瘤) |
Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarity
2024-10-10發(fā)表時(shí)間: | 2020-06-01 |
名稱/貨號: | Anti- IDH2(R172S) Mouse Monoclonal Antibody/26408 |
影響因子: | Mod Pathol IF=7.1 |
應(yīng)用范圍: | IHC(作為臨床診斷的應(yīng)用工具) |
種屬: | Human(甲狀腺乳頭癌/高細(xì)胞癌) |
IDH2 R172 Mutations Across Poorly Differentiated Sinonasal Tract Malignancies: Forty Molecularly Homogenous and Histologically Variable Cases With Favorable Outcome
2024-10-10發(fā)表時(shí)間: | 2021-09-01 |
名稱/貨號: | Anti- IDH2(R172G) Mouse Monoclonal Antibody/26231 |
影響因子: | |
應(yīng)用范圍: | IHC(作為臨床診斷的應(yīng)用工具) |
種屬: | Human(神經(jīng)內(nèi)分泌癌) |
IDH2 R172 Mutations Across Poorly Differentiated Sinonasal Tract Malignancies: Forty Molecularly Homogenous and Histologically Variable Cases With Favorable Outcome
2024-10-10發(fā)表時(shí)間: | 2921-09-01 |
名稱/貨號: | Anti- IDH2(R172S) Mouse Monoclonal Antibody/26408 |
影響因子: | |
應(yīng)用范圍: | IHC(作為臨床診斷的應(yīng)用工具) |
種屬: | Human(神經(jīng)母細(xì)胞瘤,鼻竇癌) |
Case report: Tall cell carcinoma with reversed polarity of the breast: an additional case and review of the literature
2024-10-10發(fā)表時(shí)間: | 2024-02-16 |
名稱/貨號: | Anti- IDH2(R172S) Mouse Monoclonal Antibody/26408 |
影響因子: | Frontiers in Oncology IF=4.7 |
應(yīng)用范圍: | IHC(作為臨床診斷的應(yīng)用工具) |
種屬: | Human(乳腺癌) |
Angioimmunoblastic T-Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
2024-10-09發(fā)表時(shí)間: | 2021-01-11 |
名稱/貨號: | Anti- IDH2(R172K) Mouse Monoclonal Antibody /26163 |
影響因子: | The American Journal of Surgical Pathology IF=5.6 |
應(yīng)用范圍: | IHC(作為臨床診斷的應(yīng)用工具) |
種屬: | Human (淋巴癌) |
The Diagnostic Utility of IDH2 R172 Immunohistochemistry in Tall Cell Carcinoma With Reversed Polarity of the Breast
2024-10-09發(fā)表時(shí)間: | 2022-10-12 |
名稱/貨號: | Anti- IDH2(R172S) Mouse Monoclonal Antibody/26408 |
影響因子: | Applied Immunohistochemistry & Molecular Morphology IF=1.6 |
應(yīng)用范圍: | IHC(作為臨床診斷的應(yīng)用工具) |
種屬: | Human(乳腺癌) |
A Novel Approach for the Detection and Genetic Analysis of Live Melanoma Circulating Tumor Cells
2024-10-09發(fā)表時(shí)間: | 2015-03-25 |
名稱/貨號: | Anti- BRaf(V600E) Mouse Monoclonal Antibody /26039 |
影響因子: | PLOS ONE IF=3.7 |
應(yīng)用范圍: | IF(作為臨床診斷工具的驗(yàn)證 CTC) |
種屬: | Human (黑色素瘤) |
Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature
2024-10-09發(fā)表時(shí)間: | 2016-06-01 |
名稱/貨號: | Anti- BRaf(V600E) Mouse Monoclonal Antibody /26039 |
影響因子: | Journal of Surgical Research IF=2.2 |
應(yīng)用范圍: | IHC(作為臨床診斷工具的驗(yàn)證與VE1 同等) |
種屬: | Human |
Concomitant high expression of BRAFV600E, P‐cadherin and cadherin 6 is associated with High TNM stage and lymph node metastasis in conventional papillary thyroid carcinoma
2024-10-09發(fā)表時(shí)間: | 2014-02-23 |
名稱/貨號: | Anti- BRaf(V600E) Mouse Monoclonal Antibody /26039 |
影響因子: | Clinical Endocrinology IF=3.2 |
應(yīng)用范圍: | IHC(作為臨床診斷工具的驗(yàn)證) |
種屬: | Human(甲狀腺瘤) |
技術(shù)支持:優(yōu)狐